---
title: "Amgen (AMGN) Raises 2026 Outlook as Newer Drugs Replace Aging Prolia Sales"
canonical_url: https://www.stockexpertai.com/journal/2026-11-04/amgen-amgn-raises-2026-outlook-as-newer-drugs-replace-aging-prolia-sales-5d01d194437d
last_updated: 2026-11-05T04:19:13.616Z
section: "Biotech Brief"
author: "Stock Expert AI Research"
publisher: Stock Expert AI
tickers: AMGN
content_type: journal-article
---

# Amgen (AMGN) Raises 2026 Outlook as Newer Drugs Replace Aging Prolia Sales

_Amgen's third-quarter 2026 revenue beat estimates and management raised full-year guidance, even as its older bone drugs lose sales to biosimilar copies._

![Amgen — Journal cover](/public-objects/streetnews/2026-11-04/BIOTECH_BRIEF-cover-67507e1c.jpg)
Stock Expert AI data cover: figures from Financial Modeling Prep.
Photo credit and licence on the image

Amgen (AMGN) reported third-quarter 2026 results on Nov. 3, 2026, with revenue of $10.37B against an analyst estimate of $10.07B, and raised its full-year guidance. The story is a familiar one in drug stocks: older bone drugs are losing sales to copycat versions, and newer medicines such as Repatha are growing fast enough to cover the gap, at least for now. Figures are current as of Nov. 4, 2026 and cover the quarter ended Sept. 30, 2026.

## Key facts

- **Nov. 3, 2026:** Amgen reported third-quarter (quarter ended Sept. 30, 2026) revenue of $10.37B, higher than a year earlier by 8.5%, and above the analyst estimate of $10.07B.
- **Nov. 3, 2026:** Adjusted earnings per share (EPS, profit per share) were 6.45 versus an analyst estimate of 5.79. Diluted EPS under standard accounting (GAAP) was 7.08.
- **Nov. 3, 2026:** Net income was $3.86B, higher than a year earlier by 20.1%.
- **Nov. 3, 2026:** Management raised 2026 guidance for total revenue to $38.9B to $39.7B and for adjusted EPS to $22.90 to $23.70.
- **Nov. 4, 2026:** The stock quoted at 478.48 USD, up 3.73% on the latest quote. Its 52-week range is 302.13-482.48 USD.

| Metric (Q3 ended Sept. 30) | Q3 FY2026 | Q3 FY2025 |
|---|---|---|
| Revenue | $10.37B | $9.56B |
| Operating income | $3.71B | $2.53B |
| Net income | $3.86B | $3.22B |
| Diluted EPS | 7.08 | 5.93 |

## What happened

**The theme: replacing drugs that lose protection.** Large drugmakers earn most of their profit from a handful of medicines. When patents and exclusivity end, lower-priced copies called biosimilars arrive and sales of the original can drop quickly. Investors call this a "patent cliff." The question for any such company is whether newer products grow fast enough to fill the hole. Amgen's quarter is a live example.

**The drugs fading.** Prolia, a bone-strength drug, brought in $632.0M in the quarter, and XGEVA, a related cancer-bone drug, brought in $288.0M. Both were sharply lower than a year earlier. According to Amgen's release, multiple biosimilars have launched globally. Enbrel, the arthritis drug, held at $611.0M, and the company said it faces lower net prices from U.S. Medicare price setting that took effect in 2026. Otezla ($481.0M) and TEPEZZA ($526.0M) also fell versus a year earlier; the company tied TEPEZZA's decline to inventory timing.

**The drugs filling the gap.** Repatha, a cholesterol drug, reached $1.08B, up 37% according to the call. Management said new-to-brand prescriptions rose more than 60%, helped by new trial data and updated U.S. cardiology guidelines. EVENITY, a bone drug, reached $751.0M, with sales up 39% and driven by volume growth, according to the release. TEZSPIRE, an asthma drug, reached $538.0M. UPLIZNA reached $451M and IMDELLTRA, a lung cancer treatment, reached $406M, with sales more than doubling, according to the call. Management said its six key growth drivers together grew 27% from a year earlier. Amgen's own biosimilars, which are copies of other companies' drugs, also grew, led by PAVBLU at $300M.

Murdo Gordon, an Amgen executive, said on the call: "Repatha is now the only PCSK9 inhibitor with Phase III cardiovascular outcomes evidence in both primary and secondary prevention." On IMDELLTRA, he said Amgen believes it "has the potential to transform the treatment of small cell lung cancer."

By region, FMP reports revenue of $7.26B in the United States and $2.62B outside the U.S. These two figures do not add up to total revenue of $10.37B, and FMP does not explain the gap.

## Why it matters for investors

**Margins rebuilt from a weak Q1.** The five-quarter table below shows that profitability and cash generation rebuilt after a soft Q1 FY2026 for revenue and a weak Q4 FY2025 for cash flow. Operating margin of 35.8% is up from Q1's 30.9% but still below the 39.8% of Q4 FY2025.

| Quarter | Revenue | Operating margin | Free cash flow |
|---|---|---|---|
| Q3 FY2025 (ended Sept. 30, 2025) | $9.56B | 26.4% | $4.25B |
| Q4 FY2025 (ended Dec. 31, 2025) | $9.90B | 39.8% | $961.0M |
| Q1 FY2026 (ended Mar. 31, 2026) | $8.62B | 30.9% | $1.48B |
| Q2 FY2026 (ended June 30, 2026) | $10.05B | 35.0% | $3.49B |
| Q3 FY2026 (ended Sept. 30, 2026) | $10.37B | 35.8% | $3.65B |

Free cash flow (cash left after running the business and investing in equipment) was $3.65B this quarter, lower than the year-ago quarter. The company said last year's quarter benefited from the timing of rebates and collections. Operating margin was higher than a year earlier, and revenue has risen for two straight quarters. Amgen did not buy back shares in the quarter and paid $1.36B in dividends.

**Valuation versus peers.** Amgen trades at a trailing price-to-earnings ratio (share price divided by yearly profit per share) of 27.53, with a net margin of 24.1%. Peers for comparison:

| Company | P/E (trailing) | Net margin |
|---|---|---|
| Amgen (AMGN) | 27.53 | 24.1% |
| AbbVie (ABBV) | 50.57 | 15.7% |
| AstraZeneca (AZN) | 26.58 | 17.7% |
| Bristol-Myers Squibb (BMY) | 14.20 | 18.5% |
| GSK (GSK) | 17.50 | 13.0% |

Amgen's net margin is the highest in this group, and it trades at the second-highest P/E in the group, near AstraZeneca. Other trailing measures: price-to-sales 6.64, enterprise value to EBITDA (a debt-inclusive profit multiple) 16.48, and a dividend yield of 2.1%.

**Analysts.** Of 41 ratings, 22 are buy, 16 are hold and 3 are sell, for a consensus of "Buy." The analyst price targets average 415.58 USD (median 415.00 USD), with a high of 500.00 USD and a low of 230.00 USD. The latest quote is above the average analyst target. On Nov. 4, 2026, Citigroup, Truist Securities, Canaccord Genuity and Wells Fargo kept neutral-type ratings, while UBS and Scotiabank kept positive ones.

**Stock Expert AI MoonshotScore.** Our own score for Amgen is 87 (Exceptional). The sector-relative pillars are quality 95, momentum 92, growth 69, safety 47 and valuation 44. In plain terms: strong profitability and price trend, decent growth, and weaker marks for balance sheet strength and price.

## What could go wrong

- **Debt.** Total debt was $54.01B against cash and short-term investments of $13.19B, leaving net debt of $40.82B as of Sept. 30, 2026. Debt-to-equity is 3.76 and the Altman Z-score (a bankruptcy-risk gauge) is 2.56. The Piotroski score (a 0-9 financial health check) is 8, a relatively strong reading that partly offsets the heavy debt load.
- **Costs rising.** Management expects a "meaningful sequential increase in operating expenses" in the fourth quarter, with higher profit-share expense and selling costs.
- **Competition and pricing.** Management called the Sjögren's disease space "very competitive." On obesity, an analyst, Evan Seigerman, described a rapidly evolving field, and Gordon acknowledged "the amount of activity in this category." Gordon said reimbursement for MariTide outside the U.S. is expected to be "tougher" and "very much a consumer-driven market," though he added that Amgen is hopeful outcomes data and type 2 diabetes data will help it secure reimbursement in many markets outside the U.S.
- **Pipeline and regulatory timing.** MariTide, Amgen's monthly obesity candidate, is still in late-stage trials with no launch date given. Separately, Amgen's release says the FDA's Center for Drug Evaluation and Research asked Amgen to voluntarily withdraw TAVNEOS from the U.S. market. Amgen requested a hearing on June 1, 2026, submitted supporting materials on July 23, 2026, and says it believes the drug has a favorable benefit-risk profile.
- **Insiders.** Among the 30 most recent Form 4 filings, those dated in the last 90 days show 0 open-market purchases and 2 sales. Older filings in the window may be missing.

## What to watch next

- **Fourth-quarter results.** Amgen's next earnings date is 2027-02-02, with an analyst EPS estimate of 5.73 and a revenue estimate of $10.44B.
- **Operating costs.** Whether the promised fourth-quarter cost increase pushes margins below the recent range. For 2027, CFO Thomas Dittrich said Amgen does not anticipate a step-down in operating margin compared with 2026 guidance, but gave no numbers.
- **Sjögren's data.** A second Phase 3 study of dazodalibep is due to finish in the fourth quarter of 2026; management gave no regulatory update.
- **MariTide readouts.** James Bradner, an Amgen executive, said MariTide is "emerging as the first monthly therapy for obesity." Asked about blinded tolerability data, he said the MariTide studies are following good clinical practice and that management will share more on efficacy and tolerability when the studies read out.
- **Biosimilar pressure.** Further declines in Prolia and XGEVA, and the pace of Repatha and IMDELLTRA growth.

## Frequently asked questions

## Q: Did Amgen beat earnings estimates in the third quarter of 2026?

Yes, Amgen beat on both lines for the quarter ended Sept. 30, 2026. Adjusted EPS was 6.45 versus an analyst estimate of 5.79, and revenue was $10.37B versus an estimate of $10.07B. Management also raised its full-year guidance.

## Q: Why are Amgen's Prolia sales falling?

Prolia sales are falling because lower-priced biosimilar versions have launched globally. According to Amgen's release, the drop came from lower volume plus lower net prices and changes to estimated sales deductions. Prolia brought in $632.0M in the third quarter of 2026, and the related XGEVA brought in $288.0M, both sharply lower than a year earlier.

## Q: Which Amgen drugs are driving growth now?

Repatha, EVENITY, TEZSPIRE, UPLIZNA and IMDELLTRA were among the fastest-growing products discussed on the call. Repatha was the largest at $1.08B in the third quarter of 2026. Management also pointed to MariTide, an obesity candidate still in trials, as a longer-term opportunity, but it does not yet contribute sales.




*This is educational content, not investment advice. Past performance does not guarantee future results.*

## Related Tickers
- [AMGN](https://www.stockexpertai.com/stock/amgn)

## Sources
- [Stock Expert AI AMGN page: quote, financials and MoonshotScore](https://www.stockexpertai.com/stock/amgn)
- [prnewswire.com: AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS](https://www.prnewswire.com/news-releases/amgen-reports-third-quarter-2026-financial-results-302928131.html)
- [prnewswire.com: Blue Chips Surge Past 2.8% as VIX Drops Below 18 While Oil Sinks Nearly 8%](https://www.prnewswire.com/news-releases/blue-chips-surge-past-2-8-as-vix-drops-below-18-while-oil-sinks-nearly-8-302929607.html)
- [benzinga.com: Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data](https://www.benzinga.com/markets/earnings/26/11/62878533/amgen-analyst-likes-diversified-business-remains-patient-until-maritide-obesity-data)
- [zacks.com: AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook](https://www.zacks.com/stock/news/3023059/amgn-q3-earnings-call-highlights-pipeline-and-raised-outlook?cid=CS-STOCKNEWSAPI-FT-analyst_blog_plus|earnings_call_takeaways-3023059)
- [zacks.com: AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance](https://www.zacks.com/stock/news/3022666/amgn-stock-down-despite-q3-earnings-sales-beat-raised-guidance?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-3022666)

---
_Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article. Educational research, not financial advice._